


In the Claims

Please substitute the following claims 19, 20, 22, 23, 25, 26, 34-36 and 39 for claims 19, 20, 22, 23, 25, 26, 34-36 and 39 now pending in the above-identified application.

Please cancel claims 1, 2, 4-12, 14-18, 28, 40 and 45.

Claims 1-18 (Cancelled)

19. (Currently Amended) A compound of the formula :



wherein Ar¹ is a cyclic group which may have 1 to 5 substituents selected from the group consisting of:

- (1) oxo,
- (2) halogen atoms,
- (3) C₁₋₃ alkylendioxy,
- (4) nitro,
- (5) cyano,
- (6) optionally halogenated C₁₋₆ alkyl,
- (7) hydroxy-C₁₋₆ alkyl,
- (8) carboxy-C₁₋₆ alkyl,
- (9) C₁₋₆ alkoxy-carbonyl-C₁₋₆ alkyl,
- (10) C₆₋₁₄ aryloxy-C₁₋₆ alkyl,
- (11) C₁₋₆ alkyl-C₆₋₁₄ aryl-C₂₋₆ alkenyl,

- (12) optionally halogenated C₃₋₆ cycloalkyl,
- (13) optionally halogenated C₁₋₆ alkoxy,
- (14) optionally halogenated C₁₋₆ alkylthio,
- (15) C₇₋₁₉ aralkyl,
- (16) hydroxy,
- (17) C₆₋₁₄ aryloxy,
- (18) C₇₋₁₉ aralkyloxy,
- (19) C₆₋₁₄ aryl-carbamoyl,
- (20) amino,
- (21) amino-C₁₋₆ alkyl,
- (22) mono-C₁₋₆ alkylamino,
- (23) di-C₁₋₆ alkylamino,
- (24) mono-C₁₋₆ alkylamino-C₁₋₆ alkyl,
- (25) di-C₁₋₆ alkylamino-C₁₋₆ alkyl,
- (26) 5 to 7 membered saturated cyclic amino,
- (27) 5 to 7 membered non-aromatic heterocyclic groups,
- (28) acyl,
- (29) acylamino,
- (30) acyloxy, and
- (31) aromatic hetero ring-C₁₋₆ alkoxy,

wherein the above (15), (17), (18) and (19) may have 1 to 5 substituents selected from the group consisting of halogen atom, C₁₋₃ alkylenedioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆

alkylamino, amino-C₁₋₆ alkyl, mono-C₁₋₆ alkylamino-C₁₋₆ alkyl, di-C₁₋₆ alkylamino-C₁₋₆ alkyl, formyl, carboxy, carbamoyl, thiocarbamoyl, optionally halogenated C₁₋₆ alkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, optionally halogenated C₁₋₆ alkylsulfonyl, formylamino, optionally halogenated C₁₋₆ alkyl-carboxamide, C₁₋₆ alkoxy-carboxamide, C₁₋₆ alkylsulfonylamino, C₁₋₆ alkyl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy and di-C₁₋₆ alkyl-carbamoyloxy,
the above (26) and (27) may have 1 to 5 substituents selected from the group
consisting of

1) oxo,

2) optionally halogenated C₁₋₆ alkyl,

3) optionally halogenated C₁₋₆ alkyl-carbonyl,

4) optionally halogenated C₁₋₆ alkylsulfonyl,

5) C₆₋₁₄ aryl,

6) C₇₋₁₉ aralkyl,

7) C₆₋₁₄ aryl-carbonyl,

8) 5 to 10 membered aromatic heterocyclic group which may have 1 to 5 substituents
selected from the group consisting of

8a) halogen atom,

8b) C₁₋₃ alkylendioxy,

8c) nitro,

8d) cyano,

8e) optionally halogenated C₁₋₆ alkyl,

8f) C₆₋₁₄ aryloxy-C₁₋₆ alkyl,

8g) C₁₋₆ alkyl-C₆₋₁₄ aryl-C₂₋₆ alkenyl,

8h) optionally halogenated C₃₋₆ cycloalkyl,

8i) optionally halogenated C₁₋₆ alkoxy,

8j) optionally halogenated C₁₋₆ alkylthio,

8k) C₇₋₁₉ aralkyl,

8l) hydroxy,

8m) C₆₋₁₄ aryloxy,

8n) C₇₋₁₉ aralkyloxy,

8o) amino,

8p) amino-C₁₋₆ alkyl,

8q) mono-C₁₋₆ alkylamino,

8r) di-C₁₋₆ alkylamino,

8s) mono-C₁₋₆ alkylamino-C₁₋₆ alkyl,

8t) di-C₁₋₆ alkylamino-C₁₋₆ alkyl,

8u) 5 to 7 membered saturated cyclic amino,

8v) acyl,

8w) acylamino and

8x) acyloxy, and

9) 5 to 8 membered monocyclic non-aromatic heterocyclic group,

wherein the above 5), 6), 7), 8k), 8m) and 8n) may have 1 to 5 substituents selected from the group consisting of halogen atom, C₁₋₃ alkylenedioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, amino-C₁₋₆ alkyl, mono-C₁₋₆ alkylamino-C₁₋₆ alkyl, di-C₁₋₆ alkylamino-C₁₋₆ alkyl, formyl, carboxy, carbamoyl, thiocarbamoyl, optionally halogenated C₁₋₆ alkyl-

carbonyl, C₁₋₆ alkoxy-carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, optionally halogenated C₁₋₆ alkylsulfonyl, formylamino, optionally halogenated C₁₋₆ alkyl-carboxamide, C₁₋₆ alkoxy-carboxamide, C₁₋₆ alkylsulfonylamino, C₁₋₆ alkyl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy and di-C₁₋₆ alkyl-carbamoyloxy,

provided that when the cyclic group is a non-aromatic cyclic hydrocarbon group or a non-aromatic heterocyclic group, the cyclic group may have 1 to 3 substituents selected from the group consisting of
the "C₆₋₁₄ aryl which may have substituents" as defined in the above 5), and
the "5 to 10 membered aromatic heterocyclic groups which may have substituents" as defined in the above 8);

----- is a single bond or double bond;

n is an integer of ~~1~~ 2 to 4;

X' is -CONR^{8c}-, ~~NR^{8e}CO- or CH=CH-CONR^{8e}-~~ where ~~where~~ R^{8c} is hydrogen atom or C₁₋₆ alkyl;


Y is a ~~spacer having a main chain of 1 to 6 atoms~~ C₁₋₃ alkylene;

R¹ and R² are independently hydrogen atom or a ~~hydrocarbon group which may have substituents~~ C₁₋₆ alkyl group;

R¹ and R², together with the adjacent nitrogen atom, may form a 3 to 8 membered nitrogen-containing hetero ring which ~~may have substituents; or R², together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents~~ contains at least one nitrogen atom in addition to carbon atoms, and which may further contain 1 to 3 heteroatoms selected from nitrogen, sulfur and oxygen atom,

wherein the nitrogen-containing hetero rings may have 1 to 5 substituents as defined for the above (26) “5 to 7 membered saturated cyclic amino” in the definition of Ar¹;


a ring of the formula :



~~wherein symbols have the same meanings as defined above,~~ may have further 1 to 3 substituents selected from the group consisting of formyl, optionally halogenated C₁₋₆ alkyl-carbonyl, optionally halogenated C₁₋₆ alkylsulfonyl, optionally halogenated C₁₋₆ alkyl, cyano and hydroxy;

provided that N-[2-(N,N-dimethylamino)methyl-6-tetralinyl]-4-biphenylcarboxamide is excluded; or a salt thereof.



20. (Currently Amended) A compound according to claim 19, which is of the formula :



~~wherein R¹ and R² are independently hydrogen atom or a hydrocarbon group which may have substituents; R¹ and R², together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; the other symbols have the same meanings as defined in claim 19.~~

21. (Cancelled)

22. (Currently Amended) A compound of the formula :



wherein Ar^1 is a cyclic group which may have 1 to 5 substituents selected from the group consisting of

(1) oxo,

(2) halogen atoms,

(3) C_{1-3} alkylendioxy,

(4) nitro,

(5) cyano,

(6) optionally halogenated C_{1-6} alkyl,

(7) hydroxy- C_{1-6} alkyl,

(8) carboxy- C_{1-6} alkyl,

(9) C_{1-6} alkoxy-carbonyl- C_{1-6} alkyl,

(10) C_{6-14} aryloxy- C_{1-6} alkyl,

(11) C_{1-6} alkyl- C_{6-14} aryl- C_{2-6} alkenyl,

- (12) optionally halogenated C₃₋₆ cycloalkyl,
- (13) optionally halogenated C₁₋₆ alkoxy,
- (14) optionally halogenated C₁₋₆ alkylthio,
- (15) C₇₋₁₉ aralkyl,
- (16) hydroxy,
- (17) C₆₋₁₄ aryloxy,
- (18) C₇₋₁₉ aralkyloxy,
- (19) C₆₋₁₄ aryl-carbamoyl,
- (20) amino,
- (21) amino-C₁₋₆ alkyl,
- (22) mono-C₁₋₆ alkylamino,
- (23) di-C₁₋₆ alkylamino,
- (24) mono-C₁₋₆ alkylamino-C₁₋₆ alkyl,
- (25) di-C₁₋₆ alkylamino-C₁₋₆ alkyl,
- (26) 5 to 7 membered saturated cyclic amino,
- (27) 5 to 7 membered non-aromatic heterocyclic groups,
- (28) acyl,
- (29) acylamino,
- (30) acyloxy, and
- (31) aromatic hetero ring-C₁₋₆ alkoxy,

wherein the above (15), (17), (18) and (19) may have 1 to 5 substituents selected from the group consisting of halogen atom, C₁₋₃ alkylenedioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋

6 alkylamino, amino-C₁₋₆ alkyl, mono-C₁₋₆ alkylamino-C₁₋₆ alkyl, di-C₁₋₆ alkylamino-C₁₋₆ alkyl, formyl, carboxy, carbamoyl, thiocarbamoyl, optionally halogenated C₁₋₆ alkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, optionally halogenated C₁₋₆ alkylsulfonyl, formylamino, optionally halogenated C₁₋₆ alkyl-carboxamide, C₁₋₆ alkoxy-carboxamide, C₁₋₆ alkylsulfonylamino, C₁₋₆ alkyl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy and di-C₁₋₆ alkyl-carbamoyloxy,
the above (26) and (27) may have 1 to 5 substituents selected from the group
consisting of

1) oxo,

2) optionally halogenated C₁₋₆ alkyl,

3) optionally halogenated C₁₋₆ alkyl-carbonyl,

4) optionally halogenated C₁₋₆ alkylsulfonyl,

5) C₆₋₁₄ aryl,

6) C₇₋₁₉ aralkyl,

7) C₆₋₁₄ aryl-carbonyl,

8) 5 to 10 membered aromatic heterocyclic group which may have 1 to 5 substituents
selected from the group consisting of

8a) halogen atom,

8b) C₁₋₃ alkylendioxy,

8c) nitro,

8d) cyano,

8e) optionally halogenated C₁₋₆ alkyl,

8f) C₆₋₁₄ aryloxy-C₁₋₆ alkyl,

8g) C₁₋₆ alkyl-C₆₋₁₄ aryl-C₂₋₆ alkenyl,

8h) optionally halogenated C₃₋₆ cycloalkyl,

8i) optionally halogenated C₁₋₆ alkoxy,

8j) optionally halogenated C₁₋₆ alkylthio,

8k) C₇₋₁₉ aralkyl,

8l) hydroxy,

8m) C₆₋₁₄ aryloxy,

8n) C₇₋₁₉ aralkyloxy,

8o) amino,

8p) amino-C₁₋₆ alkyl,

8q) mono-C₁₋₆ alkylamino,

8r) di-C₁₋₆ alkylamino,

8s) mono-C₁₋₆ alkylamino-C₁₋₆ alkyl,

8t) di-C₁₋₆ alkylamino-C₁₋₆ alkyl,

8u) 5 to 7 membered saturated cyclic amino,

8v) acyl,

8w) acylamino and

8x) acyloxy, and

9) 5 to 8 membered monocyclic non-aromatic heterocyclic group,

wherein the above 5), 6), 7), 8k), 8m) and 8n) may have 1 to 5 substituents selected from the group consisting of halogen atom, C₁₋₃ alkylenedioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, amino-C₁₋₆ alkyl, mono-C₁₋₆ alkylamino-C₁₋₆ alkyl, di-C₁₋₆ alkylamino-C₁₋₆ alkyl, formyl, carboxy, carbamoyl, thiocarbamoyl, optionally halogenated C₁₋₆ alkyl-

carbonyl, C₁₋₆ alkoxy-carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, optionally halogenated C₁₋₆ alkylsulfonyl, formylamino, optionally halogenated C₁₋₆ alkyl-carboxamide, C₁₋₆ alkoxy-carboxamide, C₁₋₆ alkylsulfonylamino, C₁₋₆ alkyl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy and di-C₁₋₆ alkyl-carbamoyloxy,

provided that when the cyclic group is a non-aromatic cyclic hydrocarbon group or a non-aromatic heterocyclic group, the cyclic group may have 1 to 3 substituents selected from the group consisting of

the “C₆₋₁₄ aryl which may have substituents” as defined in the above 5), and

the “5 to 10 membered aromatic heterocyclic groups which may have substituents” as defined in the above 8);

n is an integer of ~~1~~ 2 to 4;


X' is -CONR^{8c}- ~~where is -CONR^{8e}, NR^{8e}CO or CH=CH-CONR^{8e}-~~ where R^{8c} is hydrogen atom or C₁₋₆ alkyl;

Y is a ~~spacer having a main chain of 1 to 6 atoms~~ C₁₋₃ alkylene;

R¹ and R² are independently hydrogen atom or a ~~hydrocarbon group which may have substituents~~ C₁₋₆ alkyl group;

R¹ and R², together with the adjacent nitrogen atom, may form a 3 to 8 membered nitrogen-containing hetero ring which contains at least one nitrogen atom in addition to carbon atoms, and which may further contain 1 to 3 hetero atoms selected from nitrogen, sulfur and oxygen atom, wherein the nitrogen-containing hetero ring may have 1 to 5 substituents as defined for the above (26) “5 to 7 membered saturated cyclic amino” in the definition of Ar¹; may have substituents; or R², together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents;


a ring of the formula :



~~wherein n has the same meaning as defined above,~~ may have further 1 to 3 substituents selected from the group consisting of formyl, optionally halogenated C₁₋₆ alkyl-carbonyl, optionally halogenated C₁₋₆ alkylsulfonyl, optionally halogenated C₁₋₆ alkyl, cyano and hydroxy;

provided that N-[2-(N,N-dimethylamino)methyl-6-tetralinyl]-4-biphenylcarboxamide is excluded; or a salt thereof.



23. (Currently Amended) A compound according to claim 22, which is of the formula :



~~wherein R¹ and R² are independently hydrogen atom or a hydrocarbon group which may have substituents; R¹ and R², together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; the other symbols have the same meanings as defined in claim 22.~~

Claim 24 (Cancelled)

25. (Currently Amended) A compound of the formula :



wherein Ar¹ is a cyclic group which may have 1 to 5 substituents selected from the group consisting of

(1) oxo,

(2) halogen atoms,

(3) C₁₋₃ alkylendioxy,

(4) nitro,

(5) cyano,

(6) optionally halogenated C₁₋₆ alkyl,

(7) hydroxy-C₁₋₆ alkyl,

(8) carboxy-C₁₋₆ alkyl,

(9) C₁₋₆ alkoxy-carbonyl-C₁₋₆ alkyl,

(10) C₆₋₁₄ aryloxy-C₁₋₆ alkyl,

(11) C₁₋₆ alkyl-C₆₋₁₄ aryl-C₂₋₆ alkenyl,

(12) optionally halogenated C₃₋₆ cycloalkyl,

(13) optionally halogenated C₁₋₆ alkoxy,

(14) optionally halogenated C₁₋₆ alkylthio,

- (15) C₇₋₁₉ aralkyl,
- (16) hydroxy,
- (17) C₆₋₁₄ aryloxy,
- (18) C₇₋₁₉ aralkyloxy,
- (19) C₆₋₁₄ aryl-carbamoyl,
- (20) amino,
- (21) amino-C₁₋₆ alkyl,
- (22) mono-C₁₋₆ alkylamino,
- (23) di-C₁₋₆ alkylamino,
- (24) mono-C₁₋₆ alkylamino-C₁₋₆ alkyl,
- (25) di-C₁₋₆ alkylamino-C₁₋₆ alkyl,
- (26) 5 to 7 membered saturated cyclic amino,
- (27) 5 to 7 membered non-aromatic heterocyclic groups,
- (28) acyl,
- (29) acylamino,
- (30) acyloxy, and
- (31) aromatic hetero ring-C₁₋₆ alkoxy,

wherein the above (15), (17), (18) and (19) may have 1 to 5 substituents selected from the group consisting of halogen atom, C₁₋₃ alkylenedioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, amino-C₁₋₆ alkyl, mono-C₁₋₆ alkylamino-C₁₋₆ alkyl, di-C₁₋₆ alkylamino-C₁₋₆ alkyl, formyl, carboxy, carbamoyl, thiocarbamoyl, optionally halogenated C₁₋₆ alkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl,

optionally halogenated C₁₋₆ alkylsulfonyl, formylamino, optionally halogenated C₁₋₆ alkyl-carboxamide, C₁₋₆ alkoxy-carboxamide, C₁₋₆ alkylsulfonylamino, C₁₋₆ alkyl-carbonyloxy, C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy and di-C₁₋₆ alkyl-carbamoyloxy,

the above (26) and (27) may have 1 to 5 substituents selected from the group consisting of

1) oxo,

2) optionally halogenated C₁₋₆ alkyl,

3) optionally halogenated C₁₋₆ alkyl-carbonyl,

4) optionally halogenated C₁₋₆ alkylsulfonyl,

5) C₆₋₁₄ aryl,

6) C₇₋₁₉ aralkyl,

7) C₆₋₁₄ aryl-carbonyl,

8) 5 to 10 membered aromatic heterocyclic group which may have 1 to 5 substituents

selected from the group consisting of

8a) halogen atom,

8b) C₁₋₃ alkylenedioxy,

8c) nitro,

8d) cyano,

8e) optionally halogenated C₁₋₆ alkyl,

8f) C₆₋₁₄ aryloxy-C₁₋₆ alkyl,

8g) C₁₋₆ alkyl-C₆₋₁₄ aryl-C₂₋₆ alkenyl,

8h) optionally halogenated C₃₋₆ cycloalkyl,

8i) optionally halogenated C₁₋₆ alkoxy,

8j) optionally halogenated C₁₋₆ alkylthio,

8k) C₇₋₁₉ aralkyl,

8l) hydroxy,

8m) C₆₋₁₄ aryloxy,

8n) C₇₋₁₉ aralkyloxy,

8o) amino,

8p) amino-C₁₋₆ alkyl,

8q) mono-C₁₋₆ alkylamino,

8r) di-C₁₋₆ alkylamino,

8s) mono-C₁₋₆ alkylamino-C₁₋₆ alkyl,

8t) di-C₁₋₆ alkylamino-C₁₋₆ alkyl,

8u) 5 to 7 membered saturated cyclic amino,

8v) acyl,

8w) acylamino and

8x) acyloxy, and

9) 5 to 8 membered monocyclic non-aromatic heterocyclic group,

wherein the above 5), 6), 7), 8k), 8m) and 8n) may have 1 to 5 substituents selected from the group consisting of halogen atom, C₁₋₃ alkylenedioxy, nitro, cyano, optionally halogenated C₁₋₆ alkyl, optionally halogenated C₃₋₆ cycloalkyl, optionally halogenated C₁₋₆ alkoxy, optionally halogenated C₁₋₆ alkylthio, hydroxy, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, amino-C₁₋₆ alkyl, mono-C₁₋₆ alkylamino-C₁₋₆ alkyl, di-C₁₋₆ alkylamino-C₁₋₆ alkyl, formyl, carboxy, carbamoyl, thiocarbamoyl, optionally halogenated C₁₋₆ alkyl-carbonyl, C₁₋₆ alkoxy-carbonyl, mono-C₁₋₆ alkyl-carbamoyl, di-C₁₋₆ alkyl-carbamoyl, optionally halogenated C₁₋₆ alkylsulfonyl, formylamino, optionally halogenated C₁₋₆ alkyl-carboxamide, C₁₋₆ alkoxy-carboxamide, C₁₋₆ alkylsulfonylamino, C₁₋₆ alkyl-carbonyloxy,

C₁₋₆ alkoxy-carbonyloxy, mono-C₁₋₆ alkyl-carbamoyloxy and di-C₁₋₆ alkyl-carbamoyloxy,

provided that when the cyclic group is a non-aromatic cyclic hydrocarbon group or a non-aromatic heterocyclic group, the cyclic group may have 1 to 3 substituents selected from the group consisting of the “C₆₋₁₄ aryl which may have substituents” as defined in the above 5), and the “5 to 10 membered aromatic heterocyclic groups which may have substituents” as defined in the above 8);


X' is ~~CONR^{8c}, NR^{8c}CO or CH=CH-CONR^{8c}~~ where is CONR^{8c} - where R^{8c} is hydrogen atom or C₁₋₆ alkyl;

Y is a ~~spacer having a main chain of 1 to 6 atoms~~ C₁₋₃ alkylene;

R¹ and R² are independently hydrogen atom or a ~~hydrocarbon~~ C₁₋₆ alkyl group ~~which may have substituents~~;

R¹ and R², together with the adjacent nitrogen atom, may form a 3 to 8 membered nitrogen-containing hetero ring which contain at least one nitrogen atom in addition to carbon atoms, and which may further contain 1 to 3 hetero atoms selected from nitrogen, sulfur and oxygen atom, wherein the nitrogen-containing hetero ring may have 1 to 5 substituents as defined for the above (26) “5 to 7 membered saturated cyclic amino” in the definition of Ar¹ may have substituents; or R², together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents;


a ring of the formula :



may have further 1 to 3 substituents selected from the group consisting of formyl, optionally

halogenated C₁₋₆ alkyl-carbonyl, optionally halogenated C₁₋₆ alkylsulfonyl, optionally halogenated C₁₋₆ alkyl, cyano and hydroxy; or a salt thereof.

26. (Currently Amended) A compound according to claim 25, which is of the formula :



~~wherein R¹ and R² are independently hydrogen atom or a hydrocarbon group which may have substituents; R¹ and R², together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; the other symbols have the same meanings as defined in claim 25.~~

Claims 27-33 (Cancelled)

34. (Currently Amended) A compound according to claim ~~18~~ 19, which is

N-[2-(N,N-dimethylamino)methyl-6-tetralinyl]-(4'-methoxybiphenyl-4-yl)carboxamide;

4'-fluoro-N-[6-[(N,N-dimethylamino)methyl]-7,8-dihydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide;

4'-fluoro-N-[6-(1-piperidinylmethyl)-7,8-dihydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide;

4'-fluoro-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide;

(+)-4'-fluoro-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide;

(-)-4'-fluoro-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl][1,1'-

biphenyl]-4-carboxamide;

~~4'-chloro-N-[3-[(N,N-dimethylamino)methyl]-2H-chromen-7-yl][1,1'-biphenyl]-4-carboxamide;~~

4'-fluoro-N-[6-(1-pyrrolidinylmethyl)-7,8-dihydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide;

~~N-[3-[(dimethylamino)methyl]-2H-chromen-7-yl]-4'-fluoro[1,1'-biphenyl]-4-carboxamide;~~

4'-chloro-N-[6-[(dimethylamino)methyl]-5-methyl-7,8-dihydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide;

6-(4-methoxyphenyl)-N-[5-methyl-6-(1-pyrrolidinylmethyl)-7,8-dihydro-2-naphthalenyl]nicotinamide;

~~4'-chloro-N-[7-[(dimethylamino)methyl]-5,6-dihydro-3-quinolinyl][1,1'-biphenyl]-4-carboxamide;~~

4-(4-chlorophenyl)-N-[6-(1-pyrrolidinylmethyl)-7,8-dihydro-2-naphthalenyl]-3,6-dihydro-1(2H)-pyridinecarboxamide;

N-[6-[(dimethylamino)methyl]-7,8-dihydro-2-naphthalenyl]-4-(4-fluorophenyl)-1-piperidinecarboxamide;

4-(4-methoxyphenyl)-N-[6-(1-pyrrolidinylmethyl)-5-methyl-7,8-dihydro-2-naphthalenyl]-1-piperidinecarboxamide;

4'-fluoro-N-[6-[2-(1-pyrrolidinyl)ethyl]-7,8-dihydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide;

4'-chloro-N-[6-[2-(1-pyrrolidinyl)ethyl]-7,8-dihydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide;

~~4'-chloro-N-[2-[(dimethylamino)methyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl][1,1'-biphenyl]-4-carboxamide;~~

4-(4-methoxyphenyl)-N-[5-methyl-6-(1-pyrrolidinylmethyl)-7,8-dihydro-2-naphthalenyl]-1-piperidinecarboxamide;

4-(4-chlorophenyl)-N-[6-[(4-methyl-1-piperazinyl)methyl]-7,8-dihydro-2-naphthalenyl]-1-piperidinecarboxamide;

~~4'-chloro-N-[2-[(dimethylamino)methyl]-1H-inden-6-yl][1,1'-biphenyl]-4-carboxamide;~~


~~4'-fluoro-N-[2-(1-pyrrolidinylmethyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl][1,1'-biphenyl]-4-carboxamide;~~

4'-fluoro-N-[5-methyl-6-[(4-methyl-1-piperazinyl)methyl]-7,8-dihydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide;

4'-chloro-N-[5-methyl-6-[(4-methyl-1-piperazinyl)methyl]-7,8-dihydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide; or

4-(4-chlorophenyl)-N-[5-methyl-6-[(4-methyl-1-piperazinyl)methyl]-7,8-dihydro-2-naphthalenyl]-1-piperidinecarboxamide.

35. (Currently Amended) A method for preventing or treating diseases caused by a melanin-concentrating hormone in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of claim 19 ~~the formula:~~



~~wherein Ar¹ is a cyclic group which may have substituents;~~


~~X is a spacer having a main chain of 1 to 6 atoms;~~

~~Y is a bond or a spacer having a main chain of 1 to 6 atoms;~~

~~Ar is a monocyclic aromatic ring which may be condensed with a 4 to 8 membered non-aromatic ring, and may have further substituents;~~

~~R¹ and R² are independently hydrogen atom or a hydrocarbon group which may have substituents; R¹ and R², together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; R² may form a spiro ring together with Ar; or R², together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents; or a salt thereof.~~

36. (Currently Amended) A method for preventing or treating obesity in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of claim 19 the formula:-



~~wherein Ar¹ is a cyclic group which may have substituents;~~

~~X is a spacer having a main chain of 1 to 6 atoms;~~

~~Y is a bond or a spacer having a main chain of 1 to 6 atoms;~~


~~Ar is a monocyclic aromatic ring which may be condensed with a 4 to 8 membered non-aromatic ring, and may have further substituents;~~

~~R¹ and R² are independently hydrogen atom or a hydrocarbon group which may have substituents; R¹ and R², together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; R² may form a spiro ring together~~

~~with Ar; or R², together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents; or a salt thereof.~~

Claims 37 and 38 (Cancelled)

39. (Currently Amended) A method for antagonizing melanin-concentrating hormone in a mammal in need thereof, comprising administering a compound of claim 19 the formula:



~~wherein Ar¹ is a cyclic group which may have substituents;~~

~~X is a spacer having a main chain of 1 to 6 atoms;~~

~~Y is a bond or a spacer having a main chain of 1 to 6 atoms;~~

~~Ar is a monocyclic aromatic ring which may be condensed with a 4 to 8 membered non-aromatic ring, and may have further substituents;~~

~~R¹ and R² are independently hydrogen atom or a hydrocarbon group which may have substituents; R¹ and R², together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; R² may form a spiro ring together with Ar; or R², together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents; or a salt thereof to a mammal.~~

Claim 40 (Cancelled)

41. (Previously Presented) A pharmaceutical composition which comprises a compound as defined in claim 19, and a pharmaceutically acceptable carrier, diluent or excipient.

42. (Previously Presented) A pharmaceutical composition which comprises a compound as defined in claim 22 and a pharmaceutically acceptable carrier, diluent or excipient.

43. (Previously Presented) A pharmaceutical composition which comprises a compound as defined in claim 25 and a pharmaceutically acceptable carrier, diluent or excipient.

44. (Previously Presented) A pharmaceutical composition which comprises a compound as defined in claim 26 and a pharmaceutically acceptable carrier, diluent or excipient.

Claim 45 (Cancelled)